All In Biotech

NDA 020845 · Mallinckrodt Ireland

Inomax

Nitric Oxide · Inhalation · Vasodilator

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 23, 1999

Approved uses

3

Original approval plus efficacy supplements

Registered trials

478

75 Phase 3, 30 recruiting

FAERS reports

2,910

2,770 serious, 1,302 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 12, 2025.

INOmax ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. INOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Mechanism: Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature. INOmax appears to increase the partial pressure of arterial oxygen (PaO 2 ) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • INOMAX · NITRIC OXIDE 800PPM · GAS, INHALATION · Prescription · TE AA
  • INOMAX · NITRIC OXIDE 4880PPM · GAS, INHALATION · Prescription
  • INOMAX · NITRIC OXIDE 100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GAS, INHALATION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitric Oxide" as an intervention, any sponsor and status, largest first.

All 478 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use issue377
  • death364
  • off label use342
  • drug ineffective329
  • product use in unapproved indication211
  • condition aggravated200
  • oxygen saturation decreased195
  • respiratory failure152
  • pulmonary hypertension151
  • hypotension138
  • hypoxia130
  • cardiac arrest111

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200518
200643
200777
200840
200930
201040
201179
201239
201349
201455
201552
2016116
2017140
2018127
2019142
2020211
2021235
2022274
2023263
2024357
2025315
2026201

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,105 on PubMed

Sponsor: Mallinckrodt Ireland

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.